We came across a bullish thesis on Cardio Diagnostics Holdings, Inc.(CDIO) on Stock Pursuit’s Substack. In this article, we will summarize the bulls’ thesis on CDIO. Cardio Diagnostics Holdings, Inc. (CDIO)’s share was trading at $4.4 as of 3rd June according to Yahoo Finance.
A biopharmaceutical research laboratory filled with scientists, illuminated by the glow of their equipment.
Cardio Diagnostics (CDIO), currently trading below net cash with no long-term debt and $8.7 million in cash against a market cap of just $6.9 million, emerged as a compelling deep value opportunity. While unprofitable, the company is not a typical pharma play—it operates in the epigenetic cardiovascular diagnostics space with clinically approved and already-commercialized tests. Its standout technology uses an AI-driven Integrated Genetic-Epigenetic Engine™ to assess risk for coronary heart disease and other conditions.
The flagship tests—Epi+Gen CHD and PrecisionCHD—demonstrate superior sensitivity compared to traditional tools and are the only ones of their kind globally. These tests, along with platforms like ACI and HeartRisk™, position Cardio Diagnostics in rapidly growing markets: the $8.5B coronary risk assessment space, the $24B cardiac biomarker market (9.4–14.1% CAGR), and the epigenetic diagnostics segment (15.5–19% CAGR). While recent quarterly revenue dropped sharply, full-year 2024 revenue doubled, and losses narrowed, aided by lower R&D spend and increased investment in sales personnel.
Recent partnerships with medical practices suggest this pivot toward sales execution is already in motion. Though institutional interest is limited, and analyst coverage unclear, the company’s sub-net cash valuation, proven IP, and strategic positioning in preventative care make it a logical acquisition target—especially given precedent M&A activity in related diagnostics and genomics spaces. With a potential year of cash runway and peer-reviewed cost-savings data supporting commercial use, Cardio Diagnostics may offer asymmetric upside either through organic traction or a strategic buyout. For value-focused investors, it presents a low-risk, optionality-rich setup worth a small, speculative position.
We have covered a standout stock report of a bullish thesis on Fulcrum Therapeutics, Inc. (FULC) by the same author in May 2025. The article summarizes the bulls’ thesis on FULC on Stock Pursuit’s Substack. Fulcrum Therapeutics (FULC) recently surged over 110% from around $3.30 to $7.00, reflecting growing optimism but also presenting a prime opportunity to take profits.
Story Continues
